Dojolvi

Dojolvi Uses, Dosage, Side Effects, Food Interaction and all others data.

Dojolvi is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly. Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.

Dojolvi was granted FDA approval on 30 June 2020.

Dojolvi is a source of medium chain fatty acids for patients with lc-FAODs. It has a moderate duration of action and a wide therapeutic window. Patients should be counselled regarding the risk of feeding tube dysfunction and intestinal malabsorption due to pancreatic insufficiency.

Trade Name Dojolvi
Availability Prescription only
Generic Triheptanoin
Triheptanoin Other Names Glycerol triheptanoate, Glyceryl triheptanoate, Trienanthoin, Triheptanoic glyceride, Triheptanoin, Triheptylin, Trioenanthoin
Related Drugs Dojolvi
Weight 100%,
Type Oral liquid
Formula C24H44O6
Weight Average: 428.61
Monoisotopic: 428.313789137
Protein binding

Triheptanoin is approximately 80% protein bound in plasma, likely serum albumin.

Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country United States,
Last Updated: September 19, 2023 at 7:00 am
Dojolvi
Dojolvi

Uses

Dojolvi is triheptanoin is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders.

Dojolvi is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders (lc-FAODs).

Dojolvi is also used to associated treatment for these conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

How Dojolvi works

Dojolvi is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with lc-FAODs treated with triheptanoin experienced improvements in hypoglycemia, cardiomyopathy, and rhabdomyolysis.

Food Interaction

  • Take with food. Take triheptanoin with food, liquid, or formula.

Elimination Route

A single 0.3 g/kg dose of triheptanoin reaches a Cmax of 178.9 µmol/L, with a Tmax 0.5 h, and an AUC of 336.5 µmol*h/L. A single 0.4 g/kg dose of triheptanoin reaches a Cmax of 259.1 µmol/L, with a Tmax 0.8 h, and an AUC of 569.1 µmol*h/L.

Half Life

Due to multiple peak concentrations of the heptanoate metabolite, the half life of triheptanoin could not be determined.

Clearance

A single dose of 0.3 g/kg results in a mean apparent clearance of 6.05 L/h/kg for heptanoate. A single dose of 0.4 g/kg results in a mean apparent clearance of 4.31 L/h/kg for heptanoate.

Elimination Route

Dojolvi is minimally eliminated in the urine.

Innovators Monograph

You find simplified version here Dojolvi

*** Taking medicines without doctor's advice can cause long-term problems.
Share